Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Ivermectin fails to match placebo in ongoing COVID-19 study

By Brian Buntz | October 24, 2022

Ivermectin

[Image courtesy of PubChem]

Participants in a Phase 3 COVID-19 study who received the antiparasitic ivermectin fared about as well as those who got a placebo. Ivermectin recipients recovered in a median time of 12 days, while placebo recipients convalesced in 13 days on average. 

The data from the ongoing ACTIV-6 study were published in JAMA. The study authors concluded that ivermectin did not “significantly improve time to recovery.” The article concluded that the “findings do not support the use of ivermectin in patients with mild to moderate COVID-19.”

Across all arms, the study involved 1,591 vaccinated and unvaccinated participants with mild to moderate COVID-19. 

Recipients in the ivermectin arm received 400 μg/kg of ivermectin for three consecutive days. 

The ACTIV-6 study was performed when the delta and omicron variants were the main drivers of COVID-19 infections.  

Patients in the study were recruited at 93 sites located in the U.S. 

The ACTIV-6 study also tested the efficacy of the antidepressant fluvoxamine (Luvox) and the inhaled steroid fluticasone. Neither bested placebo. 

In 2020, in vitro data suggested that ivermectin may be a potential COVID-19 therapy. 

Last year, a meta-analysis published in Open Forum Infectious Diseases found some benefit of ivermectin, concluding that recipients of the antiparasitic had a 56% reduced mortality risk in patients infected with COVID-19.

Earlier in 2021, an article in the American Journal of Therapeutics mused that ivermectin could curb the risk of COVID-19-related death with moderate-certainty evidence.

The Brazilian TOGETHER trial, the most extensive randomized, outpatient study thus far to date focused on ivermectin in COVID-19, found no benefit from 400 μg/kg for three consecutive days in patients with mild to moderate coronavirus infections. 

FDA has concluded that ivermectin is ineffective against COVID-19. In addition, the agency noted that some consumers taking animal formulations of ivermectin required hospitalization. 

CDC has also warned against using ivermectin to treat the novel coronavirus, noting that the most common adverse reactions associated with ivermectin involved neurological toxicity. 

A handful of doctors have prescribed ivermectin as an experimental COVID-19 treatment. Among them is the Ukrainian-American doctor Vladimir Zelenko, who prescribed the drug along with zinc and azithromycin. The controversial physicians’ group, America’s Frontline Doctors, has also backed ivermectin as a COVID-19 therapy. Doctors associated with the group made millions by prescribing ivermectin and the malaria drug hydroxychloroquine to COVID-19 patients, according to The Intercept.  

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE